A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Agnostos Trial is a multicentric phase 2 randomized trial with a \'pick-the-winner design\' in chemonaive patients with cancer of unknown primary. It will assess the efficacy of the two best active single agent - carboplatin or gemcitabine - added to an innovative taxane back bone (nab-Paclitaxel). Agnostos trial is a part of a larger clinical and translational initiative to improve the outlook of patients with cancer of unknown primary through evaluation of novel chemotherapeutic regimens.
Epistemonikos ID: eeba2d4dcf250a475295efbb06402aea518e358e
First added on: May 12, 2024